IKN4a gene product is commonly observed in mesothelioma tumors and cell lines, while wild-type pRB expression is maintained. We have examined the biologic and potential therapeutic role of re-expressing p16 INK4a 
Introduction

Rb and p16
INK4a gene expression are inversely correlated in a variety of tumors including lung Otterson et al., 1994; Sakaguchi et al., 1996; Shapiro et al., 1995) and bladder carcinomas , as well as astrocytomas (Ueki, 1996) . This inverse correlation highlights the importance of releasing Rb-mediated suppression to entry into S-phase of the cell cycle in the development of these cancers. In a similar manner, the previously reported observation that all mesothelioma cell lines and tumors appear to express wildtype RB protein is also correlated with the absence of p16
INK4a gene product expression in virtually all of the mesothelioma tumors and cell lines examined . However, unlike other adult onset tumors, where accumulation of acquired genetic defects are common, mesotheliomas are marked by a relative absence of abnormalities in the common molecular target genes such as p53, ras, DCC, APC, or WT1 (Metcalf et al., 1992; Pass and Mew, 1996) , although frequent mutations in the NF2 gene have recently been reported (Bianchi et al., 1995; Sekido et al, 1995) . Thus, while lack of p16
INK4a expression may be one the most common, and perhaps near universal, molecular defect in mesothelioma, it may also be accompanied by relatively few other abnormalities. Correction of this single molecular defect may provide an interesting and unique biologic approach to therapy in this disease.
The initial clinical presentation of mesothelioma is usually con®ned within the pleural or peritoneal cavity (Pass and Mew, 1996) . This limited initial disease manifestation makes mesothelioma an attractive disease to attempt to treat with gene replacement therapies. Clinical trials with gene based therapies in mesothelioma have already began using the novel and interesting concept of targeting tumors with gene products that confer selective toxicity on recipient tumor cells to an administered drug (Treat et al, 1996) . Successful gene transfer in malignant pleural eusions has already been demonstrated in this disease in animal models using adenoviral vectors (Smythe et al., 1994) . In view of the near absolute lack of eective treatment for this disease, we have sought to develop reexpression of p16
INK4a in mesothelioma as a potential gene based treatment of this disease.
Results
Mesothelioma cells are easily transduced by the Adp16 vector (Figures 1 and 2) at high eciency in vitro. High levels of p16
INK4a expression were achieved after even 1 hour exposure to virus. Expression of p16
INK4a in the previously p16
INK4a negative mesothelioma cells resulted in marked hypophosphorylation of pRB (Figure 3 ), correlating with cell cycle arrest at the G 1 \S transition as expected (DeCaprio et al., 1992) (Table 1) . Interestingly, the level of pRB expression was diminished in p16
INK4a re-expressing cells consistent with previous observations in other cells types (Sandig et al., 1997) . This cell cycle arrest was followed by evidence of cell death when analysed in two of the mesothelioma cell lines tested (Table 2 ). The percentage of dead cells as measured by propidium iodide staining was increased over twofold in H2373 cells, and over ®vefold in H2461 cells, while having minimal increase in the H2087 (p16 positive/pRB positive) lung cancer cells. Cell death was seen primarily in the mesothelioma cells and correlated with growth suppression (Figure 4) . The phenomenon of cell death following re-expression of p16
INK4a in malignant cells expressing wild-type p53 has been recently documented in other cells (Sandig et al., 1997) . Mutations of p53 in mesothelioma tumors and cell lines have rarely been detected, although some have been identi®ed Pass and Mew, 1996 Figure 6 ) In order to test whether this is speci®c to p16
INK4a negative mesothelioma cells will require the generation of p16
INK4a transductants since no naturally occurring p16
INK4a mesothelioma cell lines have been identi®ed .
After demonstrating the ecient transfer of p16 INK4a positive, pRB negative cell line, the H2009 lung cancer cell line (Otterson et al., 1994) , failed to demonstrate any inhibition in cell growth following similar Adp16 treatment. A p16 INK4a positive, pRB positive colon cancer cell line, H630 (Otterson et al., 1994) , also failed to be suppressed by p16
INK4a overexpression. One of the mesothelioma cell lines, H2595, also showed evidence of some growth suppression following transduction with the Adlacz vector, although the cell number was much more diminished in the Adp16 treated cells (Figure 4b ). This eect of the Adlacz vector on H2595 cells is of interest and perhaps represents a non-speci®c eect seen only on this cell line. The remaining cell lines were largely unaected by transduction with Adlacz. In order to further delineate the mechanism of cell death that we observed following Adp16 treatment of the mesothelioma cell lines, we performed a TUNEL assay on Adp16 treated cells ( Figure 7 ). Both H2461 and H2373 mesothelioma cells treated with Adp16 demonstrated evidence of programmed cell death (Figure 7b and d) .
We next wished to test if the Adp16 vector could eect mesothelioma cells grown in an animal model. INK4a expression in mesothelioma SP Frizelle et al virus resulted in the presence of no detectable subcutaneous tumors (data not shown). At the time of injection with the Adp16 treated cells, the same mice were injected on the contralateral¯ank (the left¯ank) with identical cells treated for one hour prior to injection with the Adlacz construct. The left¯ank (Adlacz treated cells) of the mice developed tumors while no tumors were observed on the right¯anks (Adp16 treated cells) of the mice. Although subcutaneous xenografts in athymic nude mice is a model system that has been used in other studies, we wished to extend the ®ndings to an intraperitoneal xenograft which is more analogous to human mesothelioma. A similar trend, although less striking than in the subcutaneous tumors, was observed in intraperitoneal xenografts following mixing Adp16 with mesothelioma cells prior to inoculation (Table 3) .
The treatment of transformed cells prior to injection is obviously not re¯ective of the manner in which established human tumors are treated. In order to demonstrate a biologic eect on established tumors, 1610 7 H2373 cells were injected into the right and left anks of athymic mice and allowed to reach approximately 1 cc 3 in size (approximately 21 days). After measuring the individual size of the tumors, direct injections of either Adp16 (right¯ank tumor) or Adlacz (left¯ank tumor) were administered three times per week for 2 weeks (six injections per tumor). The Adp16 injected tumors were approximately 50% smaller in volume at the end of the series of injections, and showed evidence for tumor regression during the second week of injections (Figure 8 ). Although the INK4a gene product in the injected tumors ( Figure 9 ). Immunohistochemistry of these same tumors also showed localized expression of human p16
INK4a in the tumors (Figure 10a ). Expression of p16
INK4a protein was localized to approximately less than 10% of the tumor. Interestingly, the relatively focal expression of p16
INK4a that might be expected from a direct, and therefore localized, injection into the body of the tumor was accompanied by an associated decrease or loss of detectable pRB expression in the newly p16
INK4a positive portions of the tumor (Figure 10b H2373 mesothelioma cells, treatment was started with intraperitoneal injection of Adp16 three times a week for 2 weeks (six intraperitoneal treatments). These mice were contrasted to control mice which received cancer cells but no treatment at all. Animals were sacri®ced 72 h after the last injection and examined by autopsy. Mice receiving the Adp16 injections had a trend towards both smaller and less diuse intraperitoneal tumors after only six intraperitoneal treatments when compared to untreated mice, but the biologic eect over this short time period was small, as was the number of mice tested (Table 3) . Tumors from the Adp16 treated mice also demonstrated evidence of human p16
INK4a expression on immunohistochemistry ( Figure 11 ) consistent with successful intraperitoneal delivery of the p16
INK4a gene. 
Discussion
Mesothelioma is newly diagnosed in approximately 5000 patients in the United States each year (Antman et al., 1989) . The disease is infrequently cured by aggressive surgery and radiation, but largely remains an untreatable form of cancer. Despite this grim prognosis, early metastases are rare and the tumor generally is con®ned to the pleural cavity initially, followed by local invasion of surrounding tissues. There is no standard chemotherapy for the disease, and response rates to currently available agents is very low. In view of the high frequency of absence of p16
INK4a expression in the tumors, we have investigated if there is a potential role for p16
INK4a gene replacement therapy in this mesothelioma.
In the current study, we have demonstrated that a p16 INK4a adenovirus can absolutely inhibit tumor implantation in murine xenografts, as well as lead to smaller tumor size in established mesothelioma xenografts. In addition, treatment of mesothelioma cell lines with the Adp16 vector leads to direct cell death in the cell lines tested. The possibility of treating human disease with the Adp16 vector is appealing given the limited anatomic location of mesothelioma and the initial lack of metastatic disease, and adenoviral transduction in human subjects in this disease is already being tested (Treat et al., 1996) . Mesothelioma appears to be a disease that can be approached by gene transfer treatments.
Although over-expression of p16 INK4a will lead to cell cycle arrest in the presence of wild-type RB protein, this would not necessarily lead to cell death and tumor shrinkage. Recently it has been reported that p16 INK4a -mediated cell cycle arrest leads to apoptosis of transformed cells if those cells also express wild-type p53 (Sandig et al., 1997) . Although a strategy employing gene transfer of both p53 and p16
INK4a
could be used in the setting of mesothelioma, that may prove to be unnecessary given that low rate of p53 mutations detected in mesothelioma cell lines and tumors Pass and Mew, 1996) . We detected evidence of only a single cell line with a p53 mutations by immunohistochemistry, but this method of detection is subject to false negatives and false positives (Bodner et al., 1992) . Nonetheless, given the current published data, it is likely that only a small portion of mesothelioma tumors will express mutant p53 protein, or fail to lack p16
INK4a protein expression. Thus single gene (p16 Kratzke et al., 1995) . However, mutations in other proteins involved in the G 1 /S transition could also render the replacement of p16 INK4a meaningless. Rearrangements or over-expression of cyclin D family members have been reported in a wide variety of cancers, but not in mesothelioma (Sherr, 1996) . In a similar manner, mutations in the p16
INK4a associated cyclin-dependent-kinase (cdk4) have been reported in certain kindreds of familial melanoma (Wolfel et al., 1995; Zuo et al., 1996) . These reported cdk4 mutations render the kinase insensitive to p16
-mediated inhibition and thus allow continued G-phase cyclin mediated phosphorylation of pRB and lack of cell cycle arrest. If similar mutations are found to occur in mesotheliomas, this would likely abrogate any strategy designed to re-express p16
INK4a in the p16 INK4a negative cell. No such cdk4 mutations have been reported in mesotheliomas, but currently we are working to identify if such mutations are present.
Another potential mechanism of subverting the Rbmediated block to cell cycle entry involves the transforming DNA viruses and some of their associated antigens. An intriguing report documented the presence of SV40-like DNA sequences in mesothelioma (Carbone et al., 1994) . It is possible if SV40 or a related virus is present in these tumors and expressing the associated large T antigen (which can bind to pRB and`inactivate' it (DeCaprio et al., 1988) ), then eorts to manipulate the G 1 /S transition at the molecular level may prove futile. We did not attempt to identify any such sequences in the current study. Nonetheless, expression of p16
INK4a using the Adp16 vector did result in cell cycle arrest and pRB hypophosphorylation indicating that if such SV40 sequences exist in these cells, their physiologic eect on cdk4/cyclin/pRB binding are of limited signi®cance in these cell lines. However, other potential molecular targets for these viral antigens, such as p53, exist within the cell and may present alternative pathways for molecular carcinogenesis . Although mesothelioma presents a disease that may potentially be approached by gene therapy, it seems unlikely that this strategy would be capable of reaching every cancer cell. Re-expression of other tumor suppressor genes have been associated with thè bystander' eect wherein neighboring tumor cells are killed by mechanisms dependent on their proximity to tumor cells which have been recipients of a suppressing gene vector (Fujiwara et al., 1994) . It is possible that such a bystander eect may play a role in p16
mediated tumor suppression, although we have not evaluated this in the current investigation. The fact that a relatively limited number of localized injections could results in detectable tumor shrinkage (Figure 8 ) may be evidence of such a mechanism, but veri®cation of a true bystander eect awaits further study.
The ultimate utility of re-expression of p16 INK4a in mesothelioma will need to be established in clinical trials. We have demonstrated, however, that a p16 INK4a expressing vector that can be delivered in a anatomically localized disease site has the potential of not only inhibiting cell growth and tumor implantation, but also of leading to cell death and apoptosis. This vector can successfully be used in vivo to re-express p16
INK4a in mesothelioma xenografts as well. Currently, we are testing xenografts of a spectrum of human mesothelioma cell lines in the intraperitoneal model to determine if repeated injections of the p16
INK4a vector can result in a survival advantage in the animals treated with p16
. If these experiments prove successful, potential use of p16 INK4a based gene therapies in this disease will be limited by current vector eciency. The development of more ecient or less immunogenic vector systems may allow this type of therapy to be delivered in the near future to patients with this largely untreatable and highly lethal form of cancer.
Materials and methods
Cell lines and cell culture
The cell lines used in this study were derived, characterized and propagated as previously published Pass and Mew, 1996; Pass et al., 1995) . All the studies used RPMI 1640 media supplemented with 10% fetal bovine serum. The mesothelioma cell lines H513, H2373, H2595, H2461, the lung cancer (NSCLC) cell lines H2009 and H2087, and the colon carcinoma cell line H630, grow as adherent cultures in standard tissue culture dishes.
Immunoblotting
Immunoblotting for p16
INK4a and pRB was carried out as previously published . Antisera for both p16
INK4a
(rabbit polyclonal) and pRB (murine monoclonal) were obtained from PharMingen (San Diego, CA). Whole cell lysates from mesothelioma cell lines were prepared from 5610 6 cells in 1 ml of lysis buer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.1% nonidet P-40, 50 mM NaF, 1 mM phenylmethylsulfonyl¯uoride), and approximately 100 mg total protein was electroblotted onto nitrocellulose following separation on a 7.5% SDS ± PAGE gel for pRB detection and 15% SDS ± PAGE gel for detection of p16 INK4a . Nitrocellulose ®lters were blocked for 1 h using 5% dry milk/1% bovine serum albumin (BSA) in 16phosphate buered saline (PBS) and incubated overnight at 48C in a sealed bag with either a 1 : 200 dilution of the a-RB monoclonal antibody (PharMingen, San Diego, CA) or with a 1 : 1000 dilution of an a-p16
INK4a antiserum (PharMingen) in 15 ml of 5% dry milk/1% BSA in 16PBS. Detection was performed using enhanced chemiluminescence as recommended by the manufacturer (ECL, Amersham, Arlington Heights, IL) for the monoclonal RB antibody, or using 2610 6 c.p.m. of [ 125 I]protein A (Amersham) for the polyclonal p16 INK4a antiserum followed by exposure to XAR-5 ®lm.
Immunohistochemistry 5 mm paran sections were mounted on coated glass slides, baked for 20 min at 608C, and dewaxed. Following antigen retrieval , the slides were incubated for 2 h with a murine monoclonal a-human RB antibody (clone 3C8, QED, San Diego, CA) at a concentration of 1 mg/ml. For p16
INK4a immunohistochemistry, sections were immunostained with either a rabbit polyclonal a-human p16
INK4a antiserum (PharMingen) or a murine monoclonal a-human p16
INK4a antibody (clone 175 ± 405, PharMingen). The polyclonal antisera was used at a dilution of 1 : 400 at 48C as previously described Kratzke et al., 1995) . The monoclonal p16
INK4a antibody was used at a concentration of 2 mg/ml at room temperature following an antigen retrieval step in hot citrate buer. Detection for all immunohistochemistry utilized the Vector Elite kit (Burlingame, CA) with diaminobenzidine used as the chromagen and hematoxylin as a counterstain. Only nuclear staining was accepted as evidence for tumor supressor protein expression as previously described Kratzke et al., 1995) .
Cell transduction
Construction, propagation, and titering of the Adp16 and Adlacz viral vectors are described elsewhere (Grim et al., 1997) . The Adp16 expresses a functional p16
INK4a (derived from a plasmid that was a gift from Greg Otterson) that is translated from a start codon eight codons past the consensus start codon as ®rst reported (Serrano et al., 1993) . The resulting protein is slightly smaller in size than the endogenous p16 INK4a protein, yet remains fully functional in its capacity to inhibit cdk4-mediated phosphorylation and suppress cell growth Parry and Peters, 1996; Serrano et al., 1993) . In experiments involving gene transfer into mesothelioma cells, approximately 1610 5 cells were plated onto 100 mm culture dishes. The following day, Adp16 was added to cells in the presence of 2% FCS at a M.O.I. of 100 for 1 h. Media was then removed and fresh RPMI with 10% FCS was added to the cells. Cells for immunoblotting were harvested 48 h later as described. Growth suppression was evaluated at 72 h or at 7 days (depending on the experiment) by trypsinizing the culture plates and trypan blue staining the cells, followed by cell counting using a standard hematocytometer. Alternatively, in time course experiments cells were evaluated at 2, 4, and 6 days. All experiments were performed in triplicate except for cell counts of H630 and H2009 at 7 days.
TUNEL assay for apoptosis
The H2373 and H2461 mesothelioma cell lines were incubated with the Adp16 virus at an M.O.I. of 100 as previously described. After 96 h, the cells were rinsed twice in 16PBS, followed by a 30 min incubation with 16PBS INK4a expression in mesothelioma SP Frizelle et al with 1% BSA at room temperature. The cells were then incubated for 60 min at 378C in a humidi®ed chamber in the dark with either the TUNEL (In Situ Cell Death Detection Kit, Boehringer Mannheim) reaction mixture (TdT enzyme + FITC conjugated dUTP) or a negative control mixture (without TdT enzyme). Monolayers were washed three times with PBS and mounted using Fluoromont G. Fluoresecently labeled nuclei of apoptotic cells were visualized using a¯uorescent microscope. Untreated cells were used for a negative control. As a positive control, cells were treated with the apoptosis inducing chemotherapeutic agent etoposide (Bristol-Meyers Oncology) at a concentration of 10 mg/ml (Chen et al., 1997) .
Flow cytometry
1610
5 cells were incubated with 1610 10 p.f.u./ml in RPMI 1640 media plus 2% calf serum for 60 min at 378C, 5% CO 2 with intermittent shaking. After incubation, 10 ml of complete media was added to plates. Cells were harvested 72 h later by trypsinisation. The cells were washed twice in 16PBS. The cell pellet was resuspended in a 1 ml solution of sodium citrate (0.1%) and Triton-X (0.1%). Propidiun iodide (Sigma) (50 mg/ml) and DNAse free RNAse (Boehringer Mannheim) (1 mg/ml), were added to the suspension and incubated at 378C for 30 min. Cell suspension vials were wrapped in aluminum foil and kept at 48C for 1 ± 4 h. Flow cytometry and analysis were performed on a Becton Dickson FACscan. The results reported were repeated twice.
Mouse xenografts 1610 7 mesothelioma cells (H2373) were used for all injections to generate both subcutaneous and intraperitoneal tumors. Experiments using mesothelioma cells that were transduced for 1 h prior to injection were performed by mixing the mesothelioma cell with either Adp16 or Adlacz at a M.O.I. of 100 for 1 h in RPMI with 2% fetal calf serum at room temperature, washing them once in RPMI with 10% calf serum, then twice in RPMI alone, and injecting them subcutaneously in 300 ml of RPMI into the rear¯ank of athymic nude mice (Jackson Laboratory). An aliquot of the cells were assessed by trypan blue exclusion prior to injection to assure continued cell viability after Adp16 and Adlacz treatment. Adp16 treated cells were injected into the right¯ank, while the left¯ank received the Adlacz treated cells. A total of 10 mice were treated. When tumors developed to the size of approximately 1 cc 3 (on the left¯ank only as described in the Results), the animals were sacri®ced and tumors were resected for both immunohistochemistry and immunoblotting. In experiments in which established tumors were treated, 10 mice were inoculated with 1610 7 mesothelioma cells 3 weeks prior to beginning treatment with the viral vectors. Adenoviral injections were carried out in a volume of 100 ml of sterile 16PBS directly injected into the tumor. All 10 mice received injections of Adp16 on the tumor on the right¯ank, and Adlacz in the tumor on the right¯ank. Injections consisted of 1610 10 p.f.u. per injection for both vectors. Injections occurred three times a week for two weeks. The mice were sacri®ced 1 week later. Tumor measurement was carried out in two dimensions using a micrometer after the ®rst and second week. Tumor size was evaluated against the size of the tumor at the beginning of treatment (i.e. standardized against 100% of the size of the tumor 4 weeks after implanting the mesothelioma cells). In a similar manner, intraperitoneal mesothelioma xenografts were produced by inoculation of 1610 7 mesothelioma cells. After 4 weeks, treatment of the established diuse intraperitoneal tumors was carried out by direct intraperitoneal injections of adenovirus. Prior to beginning the injections, however, two mice were sacri®ced to ensure the presence of diuse xenograft implantation (data not shown). Viral vector was diluted in 1 ml of sterile 16PBS and injected directly into the abdominal cavity of the mice. Injections consisted of 1610 11 PFU per injection for both vectors (Smythe et al., 1994 ). An identical schedule to the previously described experiment was used, consisting of six treatments over 2 weeks, with the mice being sacri®ced 2 weeks later. Intraperitoneal tumors were graded in accordance with the size and location as previously described by others (Smythe et al., 1994) , with four regions (pancreas/stomach, retroperitoneo-diaphragm, mesenteric, and hepatic-portal) chosen to grade the presence and size of tumors. The presence of a tumor between 1 and 5 mm was given a score of 1. Tumors greater than 5 mm were graded as 2, while the presence of multiple or diuse tumors (thickening or matting, or 2 or more tumors greater than 5 mm in size in one location) were graded as 3.
